Release date: 2015-06-05 In the UK, the highest number of deaths from melanoma, the highest rate of melanoma, is 2,000 per year. It is the sixth largest cancer in the UK. Blocking the PD-1 immune node pathway to promote cancer immune response, the most popular drugs are Ipilimumab and Nivolumab; British doctors at the American Society of Clinical Oncology (ASCO) announced a new clinical trial data in the UK showed that the two antibodies The combination of new cancer drugs is effective in nearly 60% of patients with advanced melanoma. CT scan of melanoma patients before treatment CT scan of melanoma patients after treatment According to a BBC report, a clinical trial conducted by a British doctor for 945 patients showed that 58% of patients taking advanced "Ipilimumab and Nivolumab" had a tumor area that was reduced by at least 1/3 in one year. According to the British Cancer Research Institute, this is a new anti-cancer drug in the history of cancer treatment. It is a powerful blow to malignant cancer. James Larkin, a leading cancer research expert in the UK, said that the two new drugs can make the body's immune system recognize previously unrecognized tumors and make React and destroy it. About Ipilimumab Ipilimumab is a monoclonal antibody that blocks a molecule called cytotoxic T cell antigen-4 (CTLA-4), which weakens its ability to kill cancer cells by affecting the body's immune system. Its development company is Bristol-Myers Squibb (BMS) under the trade name Yervoy. The mechanism of action may be to help the body's immune system recognize, target and attack melanoma cancer cells. About Nivolumab (Opdivo) Nivolumab is an experimental, fully humanized IgG4, anti-apoptotic receptor 1 (PD-1) monoclonal antibody that inhibits PD-1 and programmed death ligand 1 (PD-L1/B7-H1) Binding to Programmed Death Ligand 2 (PD-L2/B7-DC). Its development company is Bristol-Myers Squibb (BMS) under the trade name Opdivo, which has been used as a monotherapy or in combination with other drugs for multiple tumor types (non-small cell lung cancer, small cell lung cancer, melanoma, kidney cells). Studies on indications such as cancer, liver cancer, blood cancer, triple-negative breast cancer, stomach cancer, and pancreatic cancer have become the first PD-1 drugs to be effective against lung cancer. 2018 US melanoma medical market sales will exceed $1 billion The cancer immunotherapy research that has emerged in recent years has brought new hopes for human conquest of cancer. Almost all biopharmaceutical giants have been strategizing in this field, hoping to share a piece of cake. Combined immunotherapy will drive the expansion of the melanoma medical market, and its total sales in the US market will exceed $1 billion by 2018. Source: Bio-Exploration Tuya Intercom, China Tuya Intercom System, Tuya Intercom Video Door Phone, Building Tuya Intercom System, Tuya Intercom Manufacturer Zhuhai Mingke Electronics Technology Co., Ltd , https://www.mingke-tech.com
